Savara to present at the h.c. wainwright bioconnect virtual conference

Austin, texas--(business wire)--savara inc. (nasdaq: svra), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the h.c. wainwright bioconnect virtual conference being held january 10-13, 2022. a webcast of the presentation will be available at 7:00 am et/4:00 am pt on january 10, 2022 on savara's website at www.savarapharma.com/investors/events-presentations/ and archived for 90 days. about savara savara is a
SVRA Ratings Summary
SVRA Quant Ranking